Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Pediococcus pentosaceus IM96 Exerts Protective Effects against Enterohemorrhagic Escherichia coli O157:H7 Infection In Vivo

  • 2021-11-30
  • Foods 10(12)
    • Haixin Li
    • Xinqiang Xie
    • Ying Li
    • Moutong Chen
    • L. Xue
    • Juan Wang
    • Jumei Zhang
    • Shi Wu
    • Qinghua Ye
    • Shuhong Zhang
    • Runshi Yang
    • Huiting Zhao
    • Lei Wu
    • Tingting Liang
    • Yu Ding
    • Qingping Wu

Abstract

Enterohemorrhagic Escherichia coli (EHEC) is a notorious and prevalent foodborne pathogen which can cause serious intestinal diseases. The antagonistic activity of probiotics against EHEC is promising, but most of the studies concerning this subject have been carried out in vitro. Specifically, the interaction between Pediococcus pentosaceus and EHEC O157:H7 in vivo has not been reported yet. In this study, we investigated the protective effect of P. pentosaceus IM96 on EHEC O157:H7-infected female mice in vivo. The results demonstrated that P. pentosaceus IM96 reduced the level of pro-inflammatory factors and increased the level of anti-inflammatory factors of EHEC O157:H7-infected mice. Furthermore, P. pentosaceus IM96 alleviated intestinal mucosal damage and increased the level of MUC-2, tight junction (TJ) proteins, and short chain fatty acids (SCFAs). The intestinal microbial community structure and the diversity and richness of the microbiota were also changed by P. pentosaceus IM96 treatment. In summary, P. pentosaceus IM96 exerted protective effects against EHEC O157:H7 via alleviating intestinal inflammation, strengthening the intestinal barrier function, and regulating intestinal microbiota, suggesting that P. pentosaceus IM96 might serve as a potential microbial agent to prevent and treat intestinal diseases caused by EHEC O157:H7 infection in the future.

Keywords: EHEC O157:H7; Pediococcus pentosaceus IM96; inflammation; intestinal barrier; intestinal microbiota; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Pediococcus pentosaceus MAK99P15PElevated Short Chain Fatty Acids (SCFAs) LevelsBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PImproved Intestinal Mucosal HealthBeneficial
Large
Pediococcus pentosaceus MAK99P15PIncreased Anti-Inflammatory LevelsBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PIncreased MUC-2 LevelsBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PIncreased Tight Junction Protein LevelsBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PModulated Intestinal Microbial CommunityBeneficial
Moderate
Pediococcus pentosaceus MAK99P15PReduced Pro-Inflammatory MarkersBeneficial
Moderate
Pediococcus pentosaceus PP06Alleviated Intestinal DamageBeneficial
Moderate
Pediococcus pentosaceus PP06Improved Intestinal Barrier FunctionBeneficial
Moderate
Pediococcus pentosaceus PP06Reduced Inflammatory ResponseBeneficial
Moderate
Pediococcus pentosaceus PP06Regulated Intestinal MicrobiotaBeneficial
Moderate
Back to top